Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy
Current cancer therapies have encountered adverse response due to poor therapeutic efficiency, severe side effects and acquired resistance to multiple drugs. Thus, there are urgent needs for finding new cancer-targeted pharmacological strategies. In this review, we summarized the current understandi...
Enregistré dans:
Auteurs principaux: | Bin-Bin Li, Bo Wang, Cheng-Ming Zhu, Di Tang, Jun Pang, Jing Zhao, Chun-Hui Sun, Miao-Juan Qiu, Zhi-Rong Qian |
---|---|
Format: | article |
Langue: | EN |
Publié: |
KeAi Communications Co., Ltd.
2019
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/c65a4a41082d4663a0cc81b8d4f5703e |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Inhibitors, PROTACs and Molecular Glues as Diverse Therapeutic Modalities to Target Cyclin-Dependent Kinase
par: Sandeep Rana, et autres
Publié: (2021) -
Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension
par: Astrid Weiss, et autres
Publié: (2019) -
Cyclin-dependent kinase 9 is required for the survival of adult Drosophila melanogaster glia
par: Lynette C. Foo
Publié: (2017) -
Cyclin-dependent Kinase 5: Novel role of gene variants identified in ADHD
par: Subhamita Maitra, et autres
Publié: (2017) -
Susceptibility of cyclin-dependent kinase inhibitor 1-deficient mice to rheumatoid arthritis arising from interleukin-1β-induced inflammation
par: Yoshinori Takashima, et autres
Publié: (2021)